EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergistic Enhancement of Antitumor Effects by Combining Abemaciclib with Desipramine

Yan Li, Yeojin Sung, Young Eun Choi iD, Yongdoo Choi, Sung-Ho Goh iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25137407 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Yan Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Technology Convergence, National Cancer Center, 323 Ilsan-ro, Goyang 10408, Gyeonggi-Do, Republic of Korea. Hauptthemen laut MEDLINE: Benzimidazoles, Aminopyridines, Drug Synergism, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, including abemaciclib, have been approved for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced, and metastatic breast cancer. Despite the high therapeutic efficacy of CDK4/6 inhibitors, they are associated with various adverse effects, including potentially fatal interstitial lung disease. Therefore, a combination of CDK4/6 inhibitors with letrozole or fulvestrant has been attempted but has demonstrated limitations in reducing adverse effects, highlighting the need to develop new combination therapies. This study proposes a combination strategy using CDK4/6 inhibitors and tricyclic antidepressants to enhance the therapeutic outcomes of these inhibitors while reducing their side effects. The therapeutic efficacies of abemaciclib and desipramine were tested in different cancer cell lines (H460, MCF7, and HCT-116). The antitumor effects of the combined abemaciclib and desipramine treatment were evaluated in a xenograft colon tumor model. In vitro cell studies have shown the synergistic anticancer effects of combination therapy in the HCT-116 cell line. The combination treatment significantly reduced tumor size compared with control or single treatment without causing apparent toxicity to normal tissues. Although additional in vivo studies are necessary, this study suggests that the combination therapy of abemaciclib and desipramine may represent a novel therapeutic approach for treating solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzimidazolesAminopyridinesDrug SynergismXenograft Model Antitumor AssaysDesipramineHumansAnimalsMiceCell Line, TumorAntineoplastic Combined Chemotherapy ProtocolsFemaleCyclin-Dependent Kinase 4Cell ProliferationMice, NudeCyclin-Dependent Kinase 6MCF-7 CellsHCT116 CellsAntineoplastic AgentsMice, Inbred BALB C

Stichwörter der Autor:innen

abemaciclibcombined therapyin vivotricyclic antidepressant

Substanzen

abemaciclibBenzimidazolesAminopyridinesDesipramineCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Antineoplastic Agents

Autor:innen und Institutionen

  • Division of Technology Convergence, National Cancer Center, 323 Ilsan-ro, Goyang 10408, Gyeonggi-Do, Republic of Korea.
  • Division of Cancer Biology, National Cancer Center, 323 Ilsan-ro, Goyang 10408, Gyeonggi-Do, Republic of Korea.

ORCID-Profile: Young Eun Choi, Sung-Ho Goh

Förderung

  • National Cancer Center

Zitieren

APA

Li, Y., Sung, Y., Choi, Y. E., Choi, Y., & Goh, S. H. (2024). Synergistic Enhancement of Antitumor Effects by Combining Abemaciclib with Desipramine. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25137407

Vancouver

Li Y, Sung Y, Choi YE, Choi Y, Goh SH. Synergistic Enhancement of Antitumor Effects by Combining Abemaciclib with Desipramine. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25137407

BibTeX
@article{Li2024,
  author = {Li, Yan and Sung, Yeojin and Choi, Young Eun and Choi, Yongdoo and Goh, Sung-Ho},
  title = {Synergistic Enhancement of Antitumor Effects by Combining Abemaciclib with Desipramine},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25137407}
}
Kostenlos starten →